Nathan Clumeck

Summary

Affiliation: CHU Saint-Pierre
Country: Belgium

Publications

  1. ncbi request reprint Epidemiology of MDR-TB in a Belgian infectious diseases unit: a 15 years review
    R Van Heurck
    CHU Saint Pierre Infectious Diseases Department, Brussels, Belgium
    Acta Clin Belg 68:321-4. 2013
  2. doi request reprint European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults
    N Clumeck
    Saint Pierre University Hospital, Department of Infectious Diseases, Brussels, Belgium
    HIV Med 9:65-71. 2008
  3. doi request reprint Sustained viral suppression and higher CD4+ T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women
    Deborah Konopnicki
    Department of Infectious Diseases and AIDS Reference Center, Saint Pierre University Hospital, Rue Haute 322, Brussels 1000, Belgium
    J Infect Dis 207:1723-9. 2013
  4. pmc High-risk human papillomavirus infection in HIV-positive African women living in Europe
    Deborah Konopnicki
    Department of Infectious Diseases, Saint Pierre University Hospital, Brussels Free University, Brussels, Belgium
    J Int AIDS Soc 16:18023. 2013
  5. doi request reprint Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load
    Stephane De Wit
    Division of Infectious Diseases, Saint Pierre University Hospital, Brussels, Belgium
    AIDS 25:1332-3. 2011
  6. ncbi request reprint Clinical value of FDG-PET/CT for the diagnosis of human immunodeficiency virus-associated fever of unknown origin: a retrospective study
    Catherine Castaigne
    Department of Nuclear Medicine, Saint Pierre University Hospital, 322 rue Haute, Brussels 1000, Belgium
    Nucl Med Commun 30:41-7. 2009
  7. pmc Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico-epidemiological study
    Nicolas Dauby
    Division of Infectious Diseases, CHU St Pierre, Universite Libre de Bruxelles, Brussels, Belgium
    J Int AIDS Soc 14:16. 2011
  8. doi request reprint 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline
    Nathan Clumeck
    Hôpital St Pierre, Brussels, Belgium
    J Antimicrob Chemother 66:1878-85. 2011
  9. ncbi request reprint Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients
    Stephane De Wit
    St Pierre University Hospital, Brussels, Belgium
    AIDS 18:2330-1. 2004

Collaborators

Detail Information

Publications9

  1. ncbi request reprint Epidemiology of MDR-TB in a Belgian infectious diseases unit: a 15 years review
    R Van Heurck
    CHU Saint Pierre Infectious Diseases Department, Brussels, Belgium
    Acta Clin Belg 68:321-4. 2013
    ..Both require longer, more expensive and more toxic treatments. MDR-TB and especially XDR-TB are associated with a lower cure rate than non MDR-TB...
  2. doi request reprint European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults
    N Clumeck
    Saint Pierre University Hospital, Department of Infectious Diseases, Brussels, Belgium
    HIV Med 9:65-71. 2008
    ....
  3. doi request reprint Sustained viral suppression and higher CD4+ T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women
    Deborah Konopnicki
    Department of Infectious Diseases and AIDS Reference Center, Saint Pierre University Hospital, Rue Haute 322, Brussels 1000, Belgium
    J Infect Dis 207:1723-9. 2013
    ..We assessed the long-term impact of cART on persistent cervical HR-HPV infection in a very large cohort of 652 women who underwent follow-up of HIV infection for a median duration of 104 months...
  4. pmc High-risk human papillomavirus infection in HIV-positive African women living in Europe
    Deborah Konopnicki
    Department of Infectious Diseases, Saint Pierre University Hospital, Brussels Free University, Brussels, Belgium
    J Int AIDS Soc 16:18023. 2013
    ..Cervical infection with high-risk human papillomavirus (HRHPV) induces cervical cancer and is present in 14% of women in Europe. We assessed the prevalence and incidence of cervical HRHPV in a cohort of HIV-positive women living in Belgium...
  5. doi request reprint Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load
    Stephane De Wit
    Division of Infectious Diseases, Saint Pierre University Hospital, Brussels, Belgium
    AIDS 25:1332-3. 2011
    ..controls, with no difference in high-sensitivity C-reactive protein (hsCRP) and CD4. These results suggest that atorvastatin reduces the level of immune activation in patients with undetectable viral load...
  6. ncbi request reprint Clinical value of FDG-PET/CT for the diagnosis of human immunodeficiency virus-associated fever of unknown origin: a retrospective study
    Catherine Castaigne
    Department of Nuclear Medicine, Saint Pierre University Hospital, 322 rue Haute, Brussels 1000, Belgium
    Nucl Med Commun 30:41-7. 2009
    ....
  7. pmc Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico-epidemiological study
    Nicolas Dauby
    Division of Infectious Diseases, CHU St Pierre, Universite Libre de Bruxelles, Brussels, Belgium
    J Int AIDS Soc 14:16. 2011
    ..Non-AIDS-defining malignancies (NADM) are becoming a major cause of mortality in the era of highly active antiretroviral therapy. We wished to investigate the incidence, risks factors and outcome of NADM in an urban cohort...
  8. doi request reprint 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline
    Nathan Clumeck
    Hôpital St Pierre, Brussels, Belgium
    J Antimicrob Chemother 66:1878-85. 2011
    ..In virologically suppressed patients, switching to darunavir/ritonavir monotherapy could avoid resistance and adverse events from continuing nucleoside analogues...
  9. ncbi request reprint Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients
    Stephane De Wit
    St Pierre University Hospital, Brussels, Belgium
    AIDS 18:2330-1. 2004
    ..However, there was a significant difference in the median CD4 cell increase at month 24. Whether this is caused by viral or immune factors warrants further investigation...